Use of in vivo phage display to engineer novel adenoviruses for targeted delivery to the cardiac vasculature

FEBS Letters

Volumn 583, Issue 12, 2009, Pages 2100-2107

  Nicol, Campbell G ^a   Denby, Laura ^a   Lopez Franco, Oscar ^a   Masson, Rachel ^a   Halliday, Crawford A ^a   Nicklin, Stuart A ^a   Kritz, Angelika ^a   Work, Lorraine M ^a   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Adenovirus; Peptide; Phage display; Vascular endothelium

Indexed keywords

ADENOVIRUS VECTOR; ASPARTYLASPARTYLTHREONYLARGINYLHISTIDINYLTRYPTOPHYLGLYCINE; CARDIOVASCULAR AGENT; UNCLASSIFIED DRUG;

ADENOVIRUS 5; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR DISEASE; CELL HOMING; CELL STRAIN HEPG2; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; ESSENTIAL HYPERTENSION; HEART BLOOD VESSEL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MICROVASCULATURE; MOLECULAR CLONING; NONHUMAN; PEPTIDE ANALYSIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ENGINEERING; RAT; STRAIN DIFFERENCE; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; VIRAL GENE DELIVERY SYSTEM; VIRUS STRAIN; WISTAR KYOTO RAT;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CARDIOVASCULAR DISEASES; CORONARY VESSELS; DISEASE MODELS, ANIMAL; DNA PRIMERS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HEPATOCYTES; HUMANS; MALE; OLIGOPEPTIDES; PEPTIDE LIBRARY; RATS; RATS, INBRED SHR; RATS, INBRED WKY;

ADENOVIRIDAE; RATTUS;

EID: 67349168759     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2009.05.037     Document Type: Article

References (18)

1. Baker A.H., Kritz A., Work L.M., and Nicklin S.A. Cell-selective viral gene delivery vectors for the vasculature. Exp. Physiol. 90 (2005) 27-31
2. Pasqualini R., Koivunen E., and Ruoslahti E. A peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrins. J. Cell Biol. 130 (1995) 1189-1196
3. Pasqualini R., and Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 380 (1996) 364-366
4. Rajotte D., Arap W., Hagedorn M., Koivunen E., Pasqualini R., and Ruoslahti E. Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J. Clin. Invest. 102 (1998) 430-437
5. Koivunen E., et al. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol. 17 (1999) 768-774
6. Zhang L., Hoffman J.A., and Ruoslahti E. Molecular profiling of heart endothelial cells. Circulation 112 (2005) 1601-1611
7. Arap W., Pasqualini R., and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998) 377-380
8. Pasqualini R., Koivunen E., and Ruoslahti E. Alpha v Integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. 15 (1997) 542-546
9. Laakkonen P., Porkka K., Hoffman J.A., and Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat. Med. 8 (2002) 751-755
10. Kalyuzhniy O., Di Paolo N., Silvestry M., Hofherr S., Barry M., Stewart P., and Shayakhmetov D. Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo. PNAS 105 (2008) 5483-5488
11. Waddington S., et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132 (2008) 397-409
12. Von Seggern D.J., et al. In vivo transduction of photoreceptors or ciliary bodies by intravital injection of pseudotyped adenoviral vectors. Mol. Ther. 7 (2003) 27-34
13. Denby L., Work L.M., Graham D., Hsu C.-L., Von Seggern D.J., Nicklin S.A., and Baker A. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum. Gene Ther. 15 (2004) 1-15
14. Denby L., Work L.M., von Seggern D.J., Wu E., McVey J., Nicklin S.A., and Baker A.H. Development of renal targeted vectors through combined in vivo phage display and capsid engineering of adenoviral fibers from serotype 19p. Mol. Ther. 15 (2007) 1647-1654
15. Work L.M., Nicol C.G., Denby L., and Baker A.H. In vivo biopanning: A methodological approach to identifying novel targeting ligands for delivery of biological agents to the vasculature. Methods Mol. Med. 108 (2005) 395-413
16. Von Seggern D.J., Huang S., Kaye-Fleck S., Stevenson S.C., and Nemerow G.R. Adenovirus vector pseudotyping in fiber expressing cell lines: improved transduction of epstein-barr virus-transformed B cells. J. Virol. 74 (2000) 354-362
17. Jakubczak J.L., Rollence M.L., Stewart D.A., Jafari J.D., Von Seggern D.J., Nemerow G.R., Stevenson S.C., and Hallenbeck P.L. Adenovirus type 5 viral particles pseudotyped with mutagenized fiber proteins show diminished infectivity of coxsackie B-adenovirus receptor-bearing cells. J. Virol. 75 (2001) 2972-2981
18. Von Seggern D.J., Chiu C.Y., Fleck S.-K., Stewart P.L., and Nemerow G.R. A helper-independent adenovirus vector with E1, E3 and fiber deleted: structure and infectivity of fiberless particles. J. Virol. 73 (1999) 1601-1608